Are there any generic drugs of amivantamab available and their market situation analysis?

Amivantamab (amivantamab) is a bispecific antibody targeting EGFR and MET dual receptors. It is mainly used to treat patients with non-small cell lung cancer carrying EGFR exon 20 insertion mutations. As a new type of targeted immunotherapy drug, evantumumab has shown good therapeutic effects in clinical practice. In 2025, the drug has just been launched in mainland China and has become a new choice for domestic lung cancer patients.

At present, the original drug of evantumumab has just been introduced in the Chinese market and has been on the market for a short time, making it difficult for domestic patients to purchase it directly. Although there are no official generic drugs available in China, patients can consider obtaining the drug through overseas channels, especially in Hong Kong, China, where the original version is available at a price of about 10,000 yuan. The existence of overseas markets provides patients with more choices, but they need to pay attention to the formality and legality of the source of drugs when purchasing.

Since evantumumab is a biological agent, its production process is complex and technical barriers are high, so the possibility of generic drugs appearing in the short term is small. The R&D and approval process for generic drugs is relatively long, and it is necessary to ensure that the efficacy and safety are equivalent to those of the original drugs. Therefore, the supply of generic drugs on the domestic and foreign markets is still relatively limited, and patients should rationally choose regular channels for medication.

Overall, evantumumab is a newly launched innovative drug. Although generic drugs are not yet popular, its important role in the treatment of lung cancer cannot be ignored. Patients should pay close attention to market dynamics and policy changes, communicate with doctors in a timely manner, and choose appropriate treatment options based on their condition and economic situation. At the same time, relevant departments and pharmaceutical companies are also actively promoting drug supply and price optimization to benefit more patients.

Reference materials:https://www.drugs.com